Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

Effectiveness of a early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants

  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 1 and
  • 1
Retrovirology20085 (Suppl 1) :P24

  • Published:


  • Lamivudine
  • Zidovudine
  • Nevirapine
  • Early Initiation
  • Viral Suppression


Vertically HIV-1-infected infants are at high risk of severe manifestations of the disease in the first year of life [1]. For this reason, we have elected, since 1996, to treat all infants born to HIV-1-infected mothers with a combination of 3 reverse transcriptase inhibitors as soon as the diagnosis of vertical transmission is established.

Material and methods

This is a cohort study of the effectiveness and tolerance of therapy in the 17 HIV-1-infected infants followed from birth in 3 belgian paediatric reference centres since 1996. All of them had been treated according to these guidelines.


Treatment was initiated in all patients before 66 days of life. All but one were asymptomatic at initiation of therapy. Median follow-up was 56 months (range: 26-103). Twelve out of the 17 patients (70.6%), including 11/13 (85%) infants treated with the combination of zidovudine, lamivudine and nevirapine, experienced a complete viral suppression (<50 copies/mL) with their first drug regimen. Lack of compliance was acknowledged by the parents of 3 of the 5 infants whose initial regimen failed. At last follow-up, 12 patients were asymptomatic, two were CDC stage A and three were stage B; 15 had HIV-1 RNA levels of < 50 copies/mL and 14 had ≥25% CD4 lymphocytes. Among them 11 were still treated with their first line regimen (Figure 1). One child experienced a transient severe side effect, another child had clinical lipodystrophy and 4 developed hypercholesterolemia.

Figure 1


Early initiation of treatment with 3 reverse transcriptase inhibitors appeared to be highly effective in this cohort of vertically HIV-1 infected infants. Parental adherence is crucial to the effectiveness of therapy.



The authors would like to thank the patients and their families for their collaboration. This study was funded by the Smiles Foundation, Belgium and Dr Van der Linden received a grant from the European AIDS Clinical Society.

Authors’ Affiliations

CHU Saint Pierre, ULB, Brussels, Belgium
CHR de La Citadelle, ULg, Liège, Belgium
AZM Koningin Paola Kinderziekenhuis, Antwerp, Belgium


  1. Gray L, Newell ML, Thorne C, Peckam C, Levy J: Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics. 2001, 108 (1): 116-22. 10.1542/peds.108.1.116.View ArticlePubMedGoogle Scholar


© Van der Linden et al.; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.